American Society of Nephrology (ASN) 2025
November 6-9, 2025 | Houston, TX
The material below is to support scientific exchange. Any content about investigational therapeutics or investigational uses of FDA-approved products does not establish the safety or efficacy of these therapeutics or uses, and there is no guarantee of FDA approval.
Alnylam does not recommend or suggest use of its products in any manner inconsistent with the approved Prescribing Information.
Final 60-Month Efficacy, Safety, and Kidney Stone Outcomes of a Phase 3 Trial of Lumasiran for Primary Hyperoxaluria Type 1 in Infants and Young Children
Long-Term Lumasiran Treatment, Kidney Function, and Isolated Kidney Transplant Outcomes in Primary Hyperoxaluria Type 1
Effect of Lumasiran on Long-Term Clinical Outcomes in Primary Hyperoxaluria Type 1: A Cohort Simulation Model
Kidney Survival in Patients with Primary Hyperoxaluria Type 1 Treated with Lumasiran Compared with Historical Controls
Comparison of Patients With Primary Hyperoxaluria 1 and Late-Stage Chronic Kidney Disease From BONAPH1DE Registry and ILLUMINATE-C Lumasiran Trial
